Perrigo Company PLC

perrigo.com

What Do They Do?

Makes and sells store-brand and branded over-the-counter self-care products, including medicines and personal-care products, to retailers, wholesalers and e-commerce sellers.

How Do They Make Money?

Customers pay under contract billing schedules, usually timed to shipment or delivery; contract manufacturing brings in revenue as products are made.

revenue

Segment	Share	Revenue
CSCA	61% FY2022: 66%
CSCI	39% FY2022: 34%

Who Are Their Customers?

North American buyers are retail chains, e-commerce retailers and wholesalers; outside the U.S. and Canada, Perrigo's pharmacy sales force serves pharmacies, wholesalers, retailers and para-pharmacies.

Customers above 10% of revenue, FY2025

of revenue from one customer

FY2024: 12% from one customer

Do Revenues Turn Into Profits?

Not on paper. It lost $1.4B in FY2025, but brought in more cash than it spent: $145.1M of free cash flow.

Operating income, FY2025

−26% of revenue

▼ Now a loss vs FY2024 ($112.9M, 3%)

Net income, FY2025

−34% of revenue

▲ +730% (Loss) vs FY2024 (−$171.8M, −4%)

Free cash flow, FY2025

3% of revenue

▼ −41% vs FY2024 ($244.6M, 6%)

How Are They Changing?

Since the FY2025 annual report

Latest quarter: Q2 FY2026, the three months to Jun 27, 2026

Revenue: ▼ −3%; vs $1.1B in Q2 FY2025
Net income: ▲ Now profitable; vs −$8.4M in Q2 FY2025

Aug 5, 2026 Reaffirmed full-year 2026 outlook The company reaffirmed its full-year outlook, citing expected sequentially higher performance in the second half.
Jun 8, 2026 CEO resigned; interim CEO appointed Patrick Lockwood-Taylor resigned, and Albert Manzone became interim president and CEO while the board searches for a permanent successor.
Apr 30, 2026 Sold Dermacosmetics business to Karo The sale closed, with upfront cash and possible additional proceeds tied to sales milestones.

Flat. Revenue was $4.3B in FY2025, about the same as the $4.1B of FY2021.

Americas geographic scope The older report's Americas segment included Latin American businesses before their disposal; the latest describes the segment as the U.S. and Canada.

Nutrition products The older report describes Nutrition as infant formula and nutritional beverages; the latest lists infant formula and oral electrolyte beverages, and says the nutritional-beverage line was exited.

Revenue over time

CSCA CSCI RX Pharmaceuticals

$5B$2.5B$0

FY2021 FY2022 FY2023 FY2024 FY2025

Who Do They Compete With?

Competes with Dr. Reddy's Labs, LNK International, PL Developments, Aurobindo, Sun Pharmaceuticals, Haleon, Kenvue, Procter & Gamble, Reckitt Benckiser, Abbott Nutrition, Bayer, Opella, Philips, Teva, Viatris, and Stada

Comments